Rena Kaminsky

Rena Kaminsky represents biotechnology, medical device, and other public and private life sciences companies in a wide range of intellectual property and commercial transactions, including corporate partnering, licenses, research and development collaborations, and manufacturing and supply arrangements.

Rena’s recent transactions include:

• Neurocrine Biosciences in its gene therapy collaboration with Voyager Therapeutics valued at $165 million upfront and up to $1.7 billion in milestone payments
• iNtRON Biotechnology in its license agreement with Roivant Sciences for endolysin biologics for treating infectious diseases
• Fate Therapeutics in its strategic collaboration with ONO Pharmaceutical for CAR-T cell cancer immunotherapies
• Arena Pharmaceuticals in its license agreement with Everest Medicines for China, Taiwan and South Korea valued at up to $212 million
• Calithera Biosciences in two clinical trial collaborations with Pfizer
• HanAll BioPharma in its $500 million license agreement with Roivant Sciences
• HanAll BioPharma in its collaboration and license agreement with Harbour BioMed for $81 million upfront and potential milestones
• Molecular Partners AG in its collaboration and option agreement with Allergan for multi-target discovery programs valued up to $1.4 billion
• Sangamo Therapeutics in its collaboration with Kite/Gilead to develop next-generation engineered cell therapies for the treatment of cancer for $150 million upfront, up to $3 billion in milestones and tiered royalties.
• Sangamo Therapeutics in its collaboration and license agreement with Pfizer to develop and commercialize gene therapy programs for hemophilia A for $70 million upfront, potential milestones up to $475 million and tiered double digit royalties.
• Calithera Biosciences in its collaboration with Incyte for the development and commercialization of CB-1158, a small molecule arginase inhibitor, including an upfront payment to Calithera of $45 million, equity investment of $8 million, milestones, profit-share in the US, and milestones and other royalties ex-US
• Takeda in its collaboration agreement with NuBiyota to develop and commercialize microbiome therapeutics for GI indications